इधर Jantar Mantar पर CJP Protest चल रहा, वहां Trump ने दिया 200% Tariff का नया झटका | Kharcha Pani

India's pharmaceutical industry has been hit by a major new challenge from the United States. US President Donald Trump has announced a phased tariff plan on imported generic medicines that could eventually reach 200%, raising concerns for Indian drugmakers that supply nearly half of America's generic medicines. In this video, we explain what Trump's tariff announcement actually means, why Indian pharma stocks and the broader stock market reacted so sharply, how India's generic medicine industry works, why China remains a crucial part of the supply chain, and what options companies like Sun Pharma, Dr. Reddy's, Cipla, Lupin, Aurobindo Pharma, and Zydus now have. Will Indian companies shift manufacturing to the US, absorb the tariff, or pass the cost on to American patients? Watch this detailed explainer to understand the impact on India's pharma exports, the stock market, and the future of one of India's most important industries. The copyright ownership in the video rests with India Today Group. No third party is permitted to use the video without obtaining the permission of India Today Group. Any permission for usage can be obtained through the email ID provided here: [email protected]. न्यूज़ लेटर के लिए क्लिक करें : https://www.thelallantop.com/newsletter खबरों को विस्तार से पढ़ने के लिए क्लिक करें यहां : https://www.thelallantop.com/ Follow us on Facebook:   / thelallantop   Follow us on X: https://x.com/TheLallantop Follow us on Instagram:   / thelallantop   Production: Shruti Agarwal Video Editor: Ved